_
Rehovot's Cancer Scientist and Weizmann Institute Graduate School Dean Yosef Yarden Joins Israel Biotech Firm as Scientific Advisory Board Member
"GammaCan International, Inc., a developer of immunotherapies for cancer and other serious conditions, today announced the appointment of Dr. Yosef Yarden to the Scientific Advisory Board, significantly broadening the scope of expertise needed to bring the Company to its next stages of development.
Gammancan is presently conducting a Phase II clinical trial of its proprietary GCAN 101 technology for the treatment of metastatic melanoma, metastatic prostate or colon cancers.
Dr. Yosef Yarden is professor in the Department of Biological Regulation at the Weizmann Institute of Science, Rehovot, Israel. His career has been devoted to understanding the role of the EGFR family of growth-factor receptors and EGF-like growth factors in human cancers. Yarden has been involved in many crucial developments in this field, including isolating the EGFR, isolating several neuregulins, establishing the pivotal role of receptor dimerization in transmembrane signaling, understanding the role of HER2 in signal transduction and tumor development, and resolving the process of ligand-induced degradation of oncogenic receptors.
Dr. Yarden is a member of the European Molecular Biology Organization and the Asia-Pacific International Molecular Biology Network. He has received numerous awards for his work, including the H. Dudley Wright Research Award in Biomembranes, the Somech Sachs Prize in Chemistry, the Andre Lwoff Prize, the Lombroso Award for Cancer Research, the Michael Bruno Prize of Yad Hanadiv (Rotchild's) Fund and Teva Founders' Prize (2004). Currently, Dr. Yarden is the Dean of the Feinberg Graduate School. In the past he served as Vice President for Academic Affairs of the Weizmann Institute of Science, Director of the M.D. Moross Cancer Research Institute, and Dean of the Faculty of Biology. He received his BSc in biology and geology (cum laude) at the Hebrew University, Jerusalem, Israel in 1979, and his PhD at the Weizmann Institute in 1985.
"Yosef Yarden's ground breaking research and regulatory expertise is critical to Gammacan as we forge ahead with Phase II clinical trials and explore potential mergers and acquisitions that would enhance the Company's product pipeline. Dr. Yarden's acceptance of this position reinforces our already strong commitment to our immunotherapy-based technologies and growth potential," stated, Dr. Dan J. Gelvan, CEO..."
Source: GammaCan Appoints Award Winning Cancer Specialist Dr. Yosef Yarden to Scientific Advisory Board; Bioregulatory and Pioneering Research Add Significant Value to Company's Endeavors. Business Wire (25 May 2005) [FullText]
Gammancan is presently conducting a Phase II clinical trial of its proprietary GCAN 101 technology for the treatment of metastatic melanoma, metastatic prostate or colon cancers.
Dr. Yosef Yarden is professor in the Department of Biological Regulation at the Weizmann Institute of Science, Rehovot, Israel. His career has been devoted to understanding the role of the EGFR family of growth-factor receptors and EGF-like growth factors in human cancers. Yarden has been involved in many crucial developments in this field, including isolating the EGFR, isolating several neuregulins, establishing the pivotal role of receptor dimerization in transmembrane signaling, understanding the role of HER2 in signal transduction and tumor development, and resolving the process of ligand-induced degradation of oncogenic receptors.
Dr. Yarden is a member of the European Molecular Biology Organization and the Asia-Pacific International Molecular Biology Network. He has received numerous awards for his work, including the H. Dudley Wright Research Award in Biomembranes, the Somech Sachs Prize in Chemistry, the Andre Lwoff Prize, the Lombroso Award for Cancer Research, the Michael Bruno Prize of Yad Hanadiv (Rotchild's) Fund and Teva Founders' Prize (2004). Currently, Dr. Yarden is the Dean of the Feinberg Graduate School. In the past he served as Vice President for Academic Affairs of the Weizmann Institute of Science, Director of the M.D. Moross Cancer Research Institute, and Dean of the Faculty of Biology. He received his BSc in biology and geology (cum laude) at the Hebrew University, Jerusalem, Israel in 1979, and his PhD at the Weizmann Institute in 1985.
"Yosef Yarden's ground breaking research and regulatory expertise is critical to Gammacan as we forge ahead with Phase II clinical trials and explore potential mergers and acquisitions that would enhance the Company's product pipeline. Dr. Yarden's acceptance of this position reinforces our already strong commitment to our immunotherapy-based technologies and growth potential," stated, Dr. Dan J. Gelvan, CEO..."
Source: GammaCan Appoints Award Winning Cancer Specialist Dr. Yosef Yarden to Scientific Advisory Board; Bioregulatory and Pioneering Research Add Significant Value to Company's Endeavors. Business Wire (25 May 2005) [FullText]
0 Comments:
Post a Comment
<< Home